InterMune completes sale of Actimmune
Gross proceeds from the sale totaled $55m, while InterMune is eligible to gain a two-year royalty stream based on net sales of Actimmune. InterMune chairman, chief executive officer
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).